Lung Cancer

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.

Adjuvant nivolumab plus chemotherapy led to a clinically meaningful reduction in relapse rates vs chemotherapy in resected NSCLC.

Misty D. Shields, MD, PhD, discusses the importance of approving novel treatments for SCLC and developmental drugs that may challenge the current paradigm.

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Results from the ALCHEMIST trial show that adjuvant crizotinib did not improve DFS or OS vs observation in resected ALK-positive NSCLC.

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Misty D. Shields, MD, PhD, discusses the inefficacy of concurrent immunotherapy and chemoradiation in lung cancer and the debate surrounding PCI in SCLC.

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Olomorasib plus pembrolizumab has been granted breakthrough therapy designation by the FDA in first-line KRAS G12C–mutated NSCLC.

The FDA has granted breakthrough therapy designation to zongertinib in the first line for nonsquamous NSCLC harboring HER2 TKD activating mutations.

Workshop faculty shared practical insights, debated sequencing, and identified opportunities to improve care for this rare, but important, disease.

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

China’s NMPA approved zongertinib tablets for unresectable, locally advanced or metastatic, previously treated NSCLC with HER2 mutations.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

TT125-802 has received FDA fast track designations in EGFR+ and KRAS G12C+ advanced NSCLC.